Shared on 03 Nov 25
Fair value Decreased 4.43%Analysts have lowered their average price target for BioMarin Pharmaceutical from about $94.80 to $90.60. This reflects a cautious view following revenue misses, reduced long-term guidance due to anticipated competition, and updated profit margin forecasts.
Shared on 20 Oct 25
Fair value Decreased 0.38%Pipeline Progress And Regulatory Support Will Unlock Rare Disease Opportunities
BioMarin Pharmaceutical's analyst price target was revised slightly lower, decreasing from $95.16 to $94.80 per share as analysts weighed ongoing competitive risks to Voxzogo and modest changes to key financial assumptions. Analyst Commentary Recent analyst coverage of BioMarin Pharmaceutical reflects a mix of optimism and caution surrounding the company's future prospects, especially regarding its growth story, competitive landscape, and valuation relative to peers.
Shared on 05 Oct 25
Fair value Decreased 1.48%Pipeline Progress And Regulatory Support Will Unlock Rare Disease Opportunities
Analysts have slightly lowered their price target for BioMarin Pharmaceutical to $95.16. This adjustment reflects carefully balanced views on future revenue growth, competitive risks affecting key drugs, and the company's ongoing potential for pipeline advancement.
Shared on 07 May 25
Fair value Decreased 1.77%Pipeline Progress And Regulatory Support Will Unlock Rare Disease Opportunities
Shared on 30 Apr 25
Fair value Decreased 1.55%Global VOXZOGO Expansion And R&D Pipeline Will Open New Markets
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 23 Apr 25
Global VOXZOGO Expansion And R&D Pipeline Will Open New Markets
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 16 Apr 25
Fair value Increased 0.62%Global VOXZOGO Expansion And R&D Pipeline Will Open New Markets
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 09 Apr 25
Fair value Increased 3.73%Global VOXZOGO Expansion And R&D Pipeline Will Open New Markets
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 02 Apr 25
Fair value Decreased 0.81%Global VOXZOGO Expansion And R&D Pipeline Will Open New Markets
Shared on 26 Mar 25
Global VOXZOGO Expansion And R&D Pipeline Will Open New Markets
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 19 Mar 25
Fair value Decreased 0.031%Global VOXZOGO Expansion And R&D Pipeline Will Open New Markets
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 10 Mar 25
Fair value Increased 0.63%Global VOXZOGO Expansion And R&D Pipeline Will Open New Markets
AnalystConsensusTarget made no meaningful changes to valuation assumptions.